Chugai to sell C&C Research Laboratories stake to JW Pharmaceutical
Category: #health  By Mateen Dalal  Date: 2019-11-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Chugai to sell C&C Research Laboratories stake to JW Pharmaceutical

Japan’s research-based pharma company, Chugai Pharmaceutical Co., Ltd. has recently made it to headlines when it agreed to change the equity structure of C&C Research Laboratories (C&C), a Korean joint venture which it formed with JW Pharmaceutical Corp.

According to reliable sources, Chugai would sell its C&C’s share to JWP by the end of this year. This would make C&C a fully owned subsidiary of JWP and would allow it to continue its research in drug discovery with independent management.

Reportedly, the move comes after both the firms agree that C&C has flourished to advance its drug candidates such as gout treatment and atopic dermatitis, and is quite capable of organizing its research programs as an independent entity. Both Chugai and JWP will maintain cordial partnerships and favorably collaborate on C&C’s latest drug candidates.

Speaking on the move, Tatsuro Kosaka, President and CEO, Chugai, said that C&C has developed numerous drug candidates which have entered the clinical study stage. The company has also attained the initial goal of creating a novel drug discovery base with superior technological abilities in Korea.

Kosaka added that Chugai values JWP’s partnership and is looking forward to seeing several ground-breaking innovations from C&C in the forthcoming years.

As per Young sub Shin, CEO, JWP, C&C has developed synergy by integrating Korea’s human infrastructure with Chugai’s knowledge on latest drug development. The company is thankful for Chugai’s continuous support ever since its inception and will work hard on growing C&C as an international R&D venture.

Prior to this news, Chugai had revealed that its “Annual Report 2018” had bagged an award in the 7th WICI Japan Award for Excellence in Integrated Reporting. Reportedly, this is the first award that the company has received from WICI Japan, which was for “the Prize for Excellence in Integrated Reporting”.

Sources cite that Chugai’s annual report was acclaimed as an outstanding example of integrated reporting with a superior level of thoroughness that grants an insightful view of the firm’s future.

Source Credit: https://www.chugai-pharm.co.jp/english/news/detail/20191127160000_672.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...